However, since the deletion of Atgl had a deleterious effect on heart function and currently available inhibitors against ATGL are not effective in humans (Trites and Clugston 2019), targeting directly ATGL for treatment of obesity and diabetes is difficult. The gene discussed is PNPLA2; the disease is obesity due to melanocortin 4 receptor deficiency.